What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
outlining stronger multi-year expectations backed by its ENHANZE drug-delivery business. The company also moved to broaden its technology base with the acquisitions of Elektrofi and Surf Bio, adding hyperconcentration capabilities that could extend the reach and royalty life of its subcutaneous delivery platforms. We'll now examine how this upgraded guidance, underpinned by momentum in the ENHANZE platform, reshapes Halozyme's investment narrative for investors. Uncover the next big thing with financially sound penny stocks that balance risk and reward For Halozyme, the core belief you'd need as a shareholder is that ENHANZE and the newer hyperconcentration technologies can support a long, royalty-rich franchise rather than a short product cycle. The sharp lift in 2025 and 2026 revenue guidance, to roughly US$1.39 billion and up to US$1.81 billion, reinforces the near-term catalyst most investors are already watching: accelerating royalty and API revenue from partners like Tak
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
- Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]Seeking Alpha
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript [Seeking Alpha]Seeking Alpha
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 1/28/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- HALO's page on the SEC website